Free Trial
NASDAQ:KOD

Kodiak Sciences (KOD) Stock Price, News & Analysis

Kodiak Sciences logo
$3.84
+0.04 (+1.05%)
(As of 11/1/2024 ET)

About Kodiak Sciences Stock (NASDAQ:KOD)

Key Stats

Today's Range
$3.79
$3.94
50-Day Range
$2.31
$3.95
52-Week Range
$1.54
$7.77
Volume
145,407 shs
Average Volume
478,905 shs
Market Capitalization
$202.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
Consensus Rating
Reduce

Company Overview

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
91st Percentile Overall Score

KOD MarketRank™: 

Kodiak Sciences scored higher than 91% of companies evaluated by MarketBeat, and ranked 102nd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 2 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Kodiak Sciences has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kodiak Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kodiak Sciences are expected to decrease in the coming year, from ($3.52) to ($3.90) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kodiak Sciences is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kodiak Sciences is -1.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kodiak Sciences has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kodiak Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    2.94% of the float of Kodiak Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kodiak Sciences has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Kodiak Sciences has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Kodiak Sciences does not currently pay a dividend.

  • Dividend Growth

    Kodiak Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.94% of the float of Kodiak Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kodiak Sciences has a short interest ratio ("days to cover") of 7.4.
  • Change versus previous month

    Short interest in Kodiak Sciences has recently decreased by 7.14%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Kodiak Sciences has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Kodiak Sciences this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for KOD on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Kodiak Sciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kodiak Sciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    45.30% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kodiak Sciences' insider trading history.
Receive KOD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter.

KOD Stock News Headlines

Kodiak Sciences Share Price (KOD.US)
Kodiak Sciences to Present at Innovate Retina 2024
Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
See More Headlines

KOD Stock Analysis - Frequently Asked Questions

Kodiak Sciences' stock was trading at $3.04 at the beginning of the year. Since then, KOD shares have increased by 26.3% and is now trading at $3.84.
View the best growth stocks for 2024 here
.

Kodiak Sciences Inc. (NASDAQ:KOD) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.01.

Kodiak Sciences (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers.

Kodiak Sciences' top institutional shareholders include SG Americas Securities LLC (0.02%). Insiders that own company stock include Bros Advisors Lp Baker, John A Borgeson, Jason Ehrlich and Victor Perlroth.
View institutional ownership trends
.

Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kodiak Sciences investors own include NVIDIA (NVDA), Datadog (DDOG), CrowdStrike (CRWD), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Splunk (SPLK).

Company Calendar

Last Earnings
8/14/2024
Today
11/01/2024
Next Earnings (Estimated)
11/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KOD
Fax
N/A
Employees
90
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.00
High Stock Price Target
$12.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+30.2%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Net Income
$-260,490,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.07 per share

Miscellaneous

Free Float
28,780,000
Market Cap
$202.06 million
Optionable
Optionable
Beta
2.34
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

This page (NASDAQ:KOD) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners